National and Kapodistrian University of Athens
Διερεύνηση της προγνωστικής αξίας του επιπέδου έκφρασης της πρωτεΪνης MCT4 στο στρώμα που περιβάλλει τα καρκινικά κύτταρα αδενοκαρκινωμάτων παχέος εντέρου και ορθοκολικών ηπατικών μεταστάσεων
Abstract
dc:descriptionThe objective was to validate the prognostic significance of the expression of Monocarboxylate Transporter 4 (MCT4) in patients with colorectal liver metastases (CRLM). In this study, we investigated the correlation between MCT4 expression in stromal and tumor cells of colorectal liver metastases (CRLM) with disease free (DFS) and overall survival (OS) in liver-only colorectal metastases treated with liver resection following neoadjuvant chemotherapy.METHODS:This is a retrospective study, of 107 patients with colorectal liver metastases. MCT4 expression in both stromal and tumor cells was studied by immunohistochemistry. The staining was scored semiquantitatively as weak, or strong. DFS and OS were calculated using both Kaplan-Meier and multivariate Cox-regression methodsRESULTS:Specimens from 57 patients (53,27%) showed weak levels of stromal MCT4 staining, whereas 50 patients (46,73%) showed strong levels of MCT4 staining. From the statistical analysis strong stromal MCT4 expression was associated with decreased DFS (HR 1.79; 95%CI, 1.12-2.85; P=0,014) and OS (HR 3.81 95%CI, 1.88-7.72; P<0,001) in univariate analysis. This finding remained significant in multivariate analysis for both DFS and OS (HR 1.95; 95%CI, 1.19-3.17; P=0.007, and HR 4.38; 95%CI, 2.15-8.92; P<0.001 respectively). Tumour MCT4 expression was not associated with DFS and OS. Five-years DFS and OS rates were 43% and 78% respectively in patients with weak and 15% and 37% respectively in patients with strong stromal MCT4 expression. CONCLUSION:Our results indicated that strong expression of stromal MCT4 in CRLM was associated with poor prognosis in patients who undergo liver resection for liver-only colorectal metastases. This finding could be further more validated in independent studies and MCT4 could be used as a new biomarker in CRLM and creates the possibility of new studies in targeted therapies.KeywordsMCT4, CRLM, colorectal cancer prognosis
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2016
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Petrides, Christos
- Πετρίδης, Χρίστος
Subjects
dc:subject × 9Rights
dc:rights- Statement dc:rights
-
- BY
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/39631